BrainStorm Cell Therapeutics Inc. Receives 1.3 Million NIS Grant from Israel’s Office of the Chief Scientist
Published: Jun 14, 2012
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell therapeutics targeting Central Nervous System (CNS) neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. received the first installment of the 2012 grant from Israel’s Office of the Chief Scientist (OCS) in the amount of approximately $350,000. The yearly grant for 2012 is $ 1,100,000 (~4.2 M NIS). The grant is awarded to BrainStorm’s Research and Development program towards the development of its leading and innovative NurOwn therapy for ALS using autologous adult stem cells.